Lenti, Marco Vincenzo, Levison, Scott, Eliadou, Elena, Willert, Robert, Kemp, Karen, Carter, Anna, Stansfield, Catherine, Assadsangabi, Arash, Singh, Salil, Crooks, Ben et al (show 13 more authors)
(2018)
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study.
DIGESTIVE AND LIVER DISEASE, 50 (12).
pp. 1299-1304.
![]() |
Text
2018 VDZ real world UK.pdf - Author Accepted Manuscript Download (417kB) |
Abstract
<h4>Background</h4>Real-life data on vedolizumab effectiveness in inflammatory bowel disease (IBD) are still emerging. Data on the comparative safety of the gut selective profile are of particular interest.<h4>Aims</h4>To assess clinical outcome and safety in IBD patients treated with vedolizumab.<h4>Methods</h4>We retrospectively collected data of patients treated with vedolizumab at eight UK hospitals (August 2014-January 2018). Clinical response and remission at 14 and 52 weeks evaluated through Physician Global Assessment (PGA) and adverse events were recorded. Possible predictors of clinical response were examined.<h4>Results</h4>Two hundred and three IBD patients (mean treatment 16 ± 8 months) were included. Of these, 135 patients (mean age 40.6 ± 16.0 years; F:M 1.9:1) had CD and 68 (mean age 44.5 ± 18.1 years; F:M 1:1.2) had UC. According to PGA, 106/135 (78.5%) CD and 62/68 (91.2%) UC patients (p = 0.02) had a clinical response/remission at 14 weeks, whereas 76/119 (63.9%) CD and 52/63 (82.5%) UC patients (p < 0.01) showed a sustained response or remission at 52 weeks, with a high adherence rate (97%). No predictors of clinical response were found. The cumulative incidence of infectious diseases was 11.9 per 100 person-years.<h4>Conclusion</h4>Vedolizumab is an effective therapy for inducing and maintaining remission of IBD, with better results for UC, and with a good safety profile.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Biological therapy, Clinical predictors, Crohn's disease, Elderly, Immunomodulator, Ulcerative colitis |
Depositing User: | Symplectic Admin |
Date Deposited: | 13 Aug 2018 06:10 |
Last Modified: | 19 Jan 2023 01:28 |
DOI: | 10.1016/j.dld.2018.07.007 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3024875 |